GenSight Biologics SA (SIGHT) AI Stock Analysis

• Market Cap: €17.40M
• Dividend Yield: N/A
• Average Volume (3M): 616.46K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.82
• Revenue Growth: -92.35%
• EPS Growth: 63.25%
• Country: FR
• Employees: 16
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.05
• Shares Outstanding: 220,890,400
• 10 Day Avg. Volume: 718,774
• 30 Day Avg. Volume: 616,456
• PEG Ratio: 0.03
• Price to Book (P/B): -0.96
• Price to Sales (P/S): 9.85
• P/FCF Ratio: -2.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €0.40
• Price Target Upside: 400.00% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: €0.08 ▼(-5.00% Downside)

The overall stock score is primarily impacted by the company's challenging financial performance, marked by persistent losses and high leverage. Technical analysis suggests neutral to slightly bearish conditions, while valuation metrics reflect ongoing financial distress. The absence of earnings call data and corporate events leaves these areas unaddressed.

Positive Factors

Proprietary gene therapy platform

A dedicated gene-therapy platform focused on rare retinal diseases is a durable competitive asset: high scientific barriers, specialized know-how and regulatory exclusivities can create long-term market entry hurdles for competitors and underpin sustained premium partnerships and licensing value.

Multiple potential revenue streams

A business model combining product sales, licensing, milestones and research collaborations diversifies cash sources. This structure can reduce single-product revenue dependence, enable milestone-driven non-linear cash inflows, and support long-term funding beyond direct sales.

Consistently high gross profit margin

Sustained high gross margins indicate favorable unit economics for the therapy portfolio. If clinical success and scale occur, these margins support operating leverage, higher long-run profitability potential, and attractive economics for partners and royalty arrangements.

Negative Factors

Negative stockholders' equity

Negative equity signals structural balance-sheet weakness that limits financial flexibility. It increases refinancing risk, may raise counterparty and partner caution, and constrains investment capacity, making sustained R&D and commercialization more dependent on external capital raises.

Negative operating cash flow and financing reliance

Persistently negative operating cash flow forces dependence on external financing or partnerships to fund operations. This reliance risks dilution, timing gaps in access to capital, and can interrupt long-term programs if funding conditions tighten, impairing execution of clinical objectives.

Volatile and steep revenue decline

Large historical revenue volatility, including a steep decline, undermines predictability needed for scaling operations and forecasting. Unstable top-line trends complicate planning, reduce bargaining power with partners, and increase execution risk for long-term commercialization strategies.

GenSight Biologics SA Business Overview & Revenue Model

Company Description

GenSight Biologics S.A., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The company develops its products through gene therapy-based mitochondrial targeting sequence and optogenetics technology platforms. Its lead product candidates include LUMEVOQ (GS010), a recombinant AAV2-based gene therapy, which is in Phase III clinical trials for the treatment of leber hereditary optic neuropathy caused by a mutated ND4 gene; and GS030, which is in Phase I/II clinical trial for the treatment of retinitis pigmentosa, as well as in preclinical stage to treat dry age-related macular degeneration. The company also develops products that are in preclinical stage targeting ophthalmic and neurodegenerative diseases. GenSight Biologics S.A. was incorporated in 2012 and is headquartered in Paris, France.

How the Company Makes Money

GenSight Biologics generates revenue through a combination of product sales, licensing agreements, and research collaborations. The company primarily focuses on advancing its gene therapy products through clinical trials and obtaining regulatory approvals to commercialize its treatments. Significant revenue streams may include potential milestone payments from partnerships with larger pharmaceutical companies, as well as royalties from the sales of approved therapies. Additionally, GenSight may engage in collaborations with academic institutions and other research organizations to further its product pipeline, which can also contribute to its earnings.

GenSight Biologics SA Financial Statement Overview

Summary

GenSight Biologics SA is in a challenging financial position, characterized by persistent losses and high leverage. Despite some revenue growth, profitability and financial stability remain significant concerns. The company's financial health is heavily reliant on external financing, which poses risks in maintaining operations and pursuing growth opportunities.

Income Statement

GenSight Biologics SA has experienced inconsistent revenue trends over the years, with a notable revenue decline in 2021 and subsequent volatility. The gross profit margin is consistently high, but the company faces significant challenges in profitability, as evidenced by consistently negative net income and EBIT margins. The recent year shows improvement in revenue but still struggles with substantial losses, indicating ongoing financial challenges.

Balance Sheet

The balance sheet reveals a negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is unfavorable due to negative equity, and return on equity is not meaningful under these circumstances. The equity ratio is also negative, highlighting a risky financial position with heavy reliance on debt.

Cash Flow

The cash flow statement indicates negative operating cash flow, but there has been improvement in free cash flow growth in recent years. However, the free cash flow to net income ratio is negative, reflecting ongoing operational challenges. The company relies heavily on financing activities to support its cash flow needs.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	945.00K	2.63M	1.27M	2.58M	5.28M	4.39M
Gross Profit	945.00K	2.63M	3.00M	2.58M	5.28M	4.39M
EBITDA	-14.12M	-14.76M	-21.73M	-26.77M	-25.52M	-34.13M
Net Income	-15.12M	-14.00M	-26.22M	-27.62M	-28.62M	-34.02M
Balance Sheet
Total Assets	7.35M	10.76M	9.13M	25.94M	56.65M	47.36M
Cash, Cash Equivalents and Short-Term Investments	270.00K	2.46M	2.13M	10.61M	44.29M	37.94M
Total Debt	19.01M	19.11M	23.54M	12.65M	12.57M	14.45M
Total Liabilities	39.46M	37.68M	39.83M	41.22M	40.66M	35.69M
Stockholders Equity	-32.11M	-26.92M	-30.67M	-15.28M	15.99M	11.75M
Cash Flow
Free Cash Flow	-8.05M	-12.94M	-24.67M	-34.01M	-17.17M	-15.05M
Operating Cash Flow	-8.05M	-12.94M	-24.66M	-33.75M	-17.14M	-15.04M
Investing Cash Flow	-48.00K	17.00K	209.00K	172.00K	-16.00K	-376.00K
Financing Cash Flow	2.15M	13.54M	15.86M	95.00K	23.74M	33.86M

GenSight Biologics SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.08
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:SIGHT, the sentiment is Negative. The current price of 0.08 is below the 20-day moving average (MA) of 0.09, below the 50-day MA of 0.10, and below the 200-day MA of 0.15, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 35.10 is Neutral, neither overbought nor oversold. The STOCH value of 19.77 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:SIGHT.

GenSight Biologics SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALDVI	49 Neutral	€24.37M	-3.50	―	―	101.95%	35.55%
ALVAL	49 Neutral	€24.87M	-1.73	―	―	―	―
POXEL	48 Neutral	€17.94M	-1.27	―	―	―	―
SIGHT	45 Neutral	€17.40M	-0.60	―	―	-92.35%	63.25%